Protect LSCs from elimination by endogenous CD8+ CTLs and adoptively transferred CD8+ CTLs in CML (30) and AML (31), respectively.Treg depletion in a prophylactic setting (32), and in a minimal residual disease setting (33) promotes anti-leukemic immunity in a murine AML model. The gene discussed is CD8A; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.